Malawi and Tanzania launch national "provided-initiated" HIV screening:
This article was originally published in Clinica
The government of Malawi is calling on the sexually-active of its population to test for HIV. The move is in response to an acknowledged lack of control of the disease and a need for better data to support prevention planning. Estimates put national prevalence at around 14% of the country's 12 million population; only 15% of the country's six million sexually-active population are thought to know their HIV status. The programme will also adopt guidance issued recently by the WHO on conducting "provider-initiated" voluntary testing, from which the patient has to actively opt out (see Clinica No 1259, p 9). Around 80% of people with HIV in sub-Saharan Africa are unaware of being infected, the WHO estimates. Tanzania, too, has just launched a national HIV-testing programme based on this guidance, Clinica understands.
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.